Literature DB >> 10361974

Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs.

S Ahlenius1.   

Abstract

A large number of ligand binding studies have shown that clozapine has a number of receptor affinities, including those of the dopamine (DA) D1 and D2 receptor families. The study of intrinsic efficacy at these receptors is less straight-forward. In the experiments summarised here, evidence is presented that clozapine behaves as an agonist at DA D1 receptors. Thus, the hypothermia produced by clozapine (2.5 mg kg(-1)) in the rat is fully antagonised by either of the selective DA D1 receptor antagonists SCH-23390 (0.1 mg kg(-1)) or NNC-687 (4 mg kg(-1)). These results provide an intriguing explanation for the clinical profile of clozapine as an atypical antipsychotic drug. Thus, there are supporting clinical and laboratory observations implicating DA D1 receptors in the prefrontal cortex in cognitive functions. Finally, clozapine displays features with regard to extrapyramidal motor mechanisms, and seizure thresholds, that could be explained by its properties as a DA D1 receptor agonist.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361974     DOI: 10.1111/j.1600-0773.1999.tb01482.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  9 in total

1.  Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study.

Authors:  Yuan-Hwa Chou; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2006-01-05       Impact factor: 4.530

2.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.

Authors:  István Gyertyán; Katalin Sághy; Judit Laszy; Ottilia Elekes; Rita Kedves; Larisza I Gémesi; Gabriella Pásztor; Mária Zájer-Balázs; Margit Kapás; Eva Agai Csongor; György Domány; Béla Kiss; Zsolt Szombathelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-12       Impact factor: 3.000

Review 3.  α2-Adrenoceptors are targets for antipsychotic drugs.

Authors:  Jan Brosda; Florian Jantschak; Heinz H Pertz
Journal:  Psychopharmacology (Berl)       Date:  2014-02-02       Impact factor: 4.530

4.  Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex.

Authors:  T Abekawa; K Ito; T Koyama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-14       Impact factor: 3.000

5.  Involvement of different types of dopamine receptors in the formation of latent inhibition of a conditioned passive avoidance reaction in rats.

Authors:  L V Loskutova; N V Kostyunina; N I Dubrovina
Journal:  Neurosci Behav Physiol       Date:  2010-05-21

6.  Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study.

Authors:  R Bodén; J Persson; A Wall; M Lubberink; L Ekselius; E-M Larsson; G Antoni
Journal:  Transl Psychiatry       Date:  2017-03-07       Impact factor: 6.222

Review 7.  Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016.

Authors:  Susann Schröder; Matthias Scheunemann; Barbara Wenzel; Peter Brust
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

Review 8.  Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring.

Authors:  Klaas E Stephan; Karl J Friston; Chris D Frith
Journal:  Schizophr Bull       Date:  2009-01-20       Impact factor: 9.306

9.  A case report of acute hypothermia during initial inpatient clozapine titration with review of current literature on clozapine-induced temperature dysregulations.

Authors:  Bradley G Burk; Alex H Ward; Brooke Clark
Journal:  BMC Psychiatry       Date:  2020-06-09       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.